로딩 중...
52주 최고가 대비 80.6% 위치
InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radio frequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States, Europe, Asia, and internationally. It offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures. The company also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions. In addition, it offers hands-free medical aesthetic products that target a range of procedures, such as skin tightening, fat reduction, and muscle stimulation. The company sells and markets its products in the United States, Canada, the United Kingdom, Ireland, Spain, Portugal, France, Belgium, Luxemburg, Italy, Germany, Austria, Japan, Australia, and India through distributors. The company was formerly known as Invasix Ltd. and changed its name to InMode Ltd. in November 2017. The company was incorporated in 2008 and is headquartered in Yokne'am, Israel.
SEC 13F 공시 기준 · 2026-Q1
SEC 13F 공시 기준 데이터입니다. 실제 현재 보유 현황과 다를 수 있으며, 투자 자문·권유·추천이 아닙니다.
| 재무 항목 | 2021년 | 2022년 | 2023년 | 2024년 | 2025년 |
|---|---|---|---|---|---|
| 주요 재무실적 (USD) | |||||
| 매출액 | - | $454.3M | $492.0M | $394.8M | $370.5M |
| 영업이익 | - | $197.9M | $195.7M | $112.5M | $85.4M |
| 당기순이익 | - | $161.5M | $197.9M | $181.3M | $93.8M |
| 잉여현금흐름 (FCF) | - | $180.0M | $176.1M | $132.0M | $84.3M |
| 수익성 비율 | |||||
| 영업이익률 | - | 43.6% | 39.8% | 28.5% | 23.0% |
| 순이익률 | - | 35.6% | 40.2% | 45.9% | 25.3% |
| ROE (자기자본이익률) | - | 29.1% | 25.1% | 25.8% | 13.7% |
| ROA (자산이익률) | - | 25.1% | 22.9% | 23.1% | 12.2% |
| 성장성 비율 | |||||
| 매출 성장률 (YoY) | - | - | 8.3% | -19.8% | -6.2% |
| EPS 성장률 (YoY) | - | - | 21.7% | -2.2% | -36.4% |
| 투자 지표 & 가치배수 | |||||
| PER (주가수익배수) | - | 18.5x | 10.3x | 7.6x | 11.0x |
| PBR (주가순자산배수) | - | 3.8x | 1.8x | 1.5x | 1.4x |
| PSR (주가매출배수) | - | 4.7x | 2.9x | 2.7x | 2.6x |
| FCF Yield | - | 8.4% | 12.2% | 12.6% | 8.8% |
| 재무 건전성 (안정성) | |||||
| 부채비율 (D/E) | - | 0.01 | 0.01 | 0.01 | 0.01 |
| 유동비율 | - | 7.67 | 13.18 | 10.23 | 9.88 |
MOLINA HEALTHCARE INC
$179.86
$9.4B